Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.
AB-506
Aminoindane
CHB
Capsid inhibitor
HBV
pgRNA encapsidation
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
28
08
2021
revised:
19
11
2021
accepted:
22
11
2021
pubmed:
27
11
2021
medline:
25
2
2022
entrez:
26
11
2021
Statut:
ppublish
Résumé
AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC
Identifiants
pubmed: 34826506
pii: S0166-3542(21)00201-1
doi: 10.1016/j.antiviral.2021.105211
pii:
doi:
Substances chimiques
Antiviral Agents
0
Viral Core Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105211Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.